https://www.nasdaq.com/press-release/aegis-capital-corp.-acted-as-sole-bookrunner-on-a-%242-million-public-offering-of
https://www.nasdaq.com/press-release/avenue-therapeutics-announces-closing-of-public-offering-of-common-stock-2021-12-15
https://www.nasdaq.com/press-release/avenue-therapeutics-prices-%242.0-million-underwritten-public-offering-of-common-stock
https://www.nasdaq.com/press-release/avenue-therapeutics-announces-fda-advisory-committee-meeting-to-review-iv-tramadol
https://www.nasdaq.com/press-release/avenue-therapeutics-announces-exercise-and-closing-of-underwriters-over-allotment
https://www.nasdaq.com/press-release/aegis-capital-corp.-acted-as-sole-bookrunner-on-a-%242.6-million-public-offering-of
https://www.nasdaq.com/press-release/avenue-therapeutics-announces-closing-of-public-offering-of-common-stock-2021-11-12
https://www.nasdaq.com/press-release/avenue-therapeutics-prices-%242.6-million-underwritten-public-offering-of-common-stock
https://www.nasdaq.com/press-release/avenue-therapeutics-receives-interim-response-to-its-formal-dispute-resolution
https://www.nasdaq.com/press-release/avenue-therapeutics-receives-complete-response-letter-from-the-fda-for-iv-tramadol-0
https://www.nasdaq.com/press-release/avenue-therapeutics-announces-that-the-fda-is-still-reviewing-its-nda-resubmission
https://www.nasdaq.com/press-release/avenue-therapeutics-announces-publication-of-real-world-data-on-nonmedical-use-of
https://www.nasdaq.com/press-release/avenue-therapeutics-announces-publication-of-tramadol-non-medical-use-in-four
https://www.nasdaq.com/press-release/avenue-therapeutics-provides-regulatory-update-for-iv-tramadol-2020-12-17
https://www.nasdaq.com/press-release/avenue-therapeutics-receives-complete-response-letter-from-the-fda-for-iv-tramadol
https://www.nasdaq.com/press-release/avenue-therapeutics-announces-publication-of-a-review-of-iv-tramadol-2020-09-09
https://www.nasdaq.com/press-release/avenue-therapeutics-reports-second-quarter-2020-financial-results-and-recent
https://www.nasdaq.com/press-release/avenue-therapeutics-announces-publication-of-phase-3-bunionectomy-study-results-2020
https://www.nasdaq.com/press-release/avenue-therapeutics-announces-publications-in-peer-reviewed-journals-2020-06-05
https://www.nasdaq.com/press-release/avenue-therapeutics-to-host-virtual-annual-meeting-of-stockholders-2020-05-29
https://www.nasdaq.com/press-release/avenue-therapeutics-reports-first-quarter-2020-financial-results-and-recent-corporate
https://www.nasdaq.com/press-release/avenue-therapeutics-announces-presentation-of-iv-tramadol-e-posters-2020-04-23
https://www.nasdaq.com/press-release/avenue-therapeutics-reports-full-year-2019-financial-results-and-recent-corporate
https://www.nasdaq.com/press-release/avenue-therapeutics-announces-new-drug-application-for-iv-tramadol-accepted-for
https://www.nasdaq.com/press-release/avenue-therapeutics-announces-submission-of-new-drug-application-for-iv-tramadol-2019
https://www.nasdaq.com/press-release/avenue-therapeutics-reports-third-quarter-2019-financial-results-and-recent-corporate
https://www.nasdaq.com/press-release/avenue-therapeutics-announces-publication-of-iv-tramadol-phase-1-clinical-data-in
https://www.nasdaq.com/press-release/avenue-therapeutics-to-present-phase-3-bunionectomy-study-of-iv-tramadol-at-the
